The HPRA framework and peptide research in Ireland

When people ask what the regulatory picture looks like for peptides in Ireland, the honest answer is: complex, consequential, and frequently misunderstood. The HPRA does not operate in a vacuum — it enforces Irish and EU legislation, works within a framework set partly in Dublin and partly in Amsterdam, and is actively engaged with the question of GLP-1 analogues circulating outside of licensed channels. Understanding the framework does not require a legal qualification. It does require reading the right sources, in the right order. That is what this article attempts to do.

What the HPRA is and what it does

The Health Products Regulatory Authority is Ireland’s national competent authority (NCA) for medicines and health products. It was established under the Irish Medicines Board Acts and has since expanded its remit considerably. Its core responsibilities include:

• Evaluating and authorising medicinal products for the Irish market
• Monitoring the quality, safety, and efficacy of authorised products
• Enforcing legislation relating to the supply of medicines, including unlicensed products
• Participating in EU-level regulatory cooperation through the EMA network
• Issuing public alerts about counterfeit or substandard health products

The HPRA publishes its decisions, product information, and public safety warnings on hpra.ie. This is the primary reference point for anyone seeking accurate, current information about the regulatory status of any compound in Ireland.

The EU framework: Directive 2001/83/EC and EMA centralised authorisation

Ireland is an EU member state and therefore implements EU pharmaceutical legislation. Two instruments are especially relevant here:

• Directive 2001/83/EC on medicinal products for human use — this is the foundational EU law defining what counts as a medicinal product and what is required before it can be placed on the market. Ireland transposed this directive into national law. Any product that falls within the directive’s definition requires either a national marketing authorisation (granted by the HPRA) or a centralised authorisation (granted by the European Commission following an EMA recommendation).
• Regulation (EC) No 726/2004 — this regulation establishes the centralised procedure for marketing authorisation. Medicines authorised centrally through the EMA are valid across all EU member states simultaneously, including Ireland.

GLP-1 receptor agonists authorised under this system — such as semaglutide injection (Ozempic/Wegovy), which holds EMA marketing authorisation — may be legally prescribed and supplied in Ireland by licensed practitioners. Unapproved versions of these same molecules do not benefit from any such authorisation.

How the HPRA classifies peptides: the medicinal product definition

The critical question for any synthetic peptide is whether it meets the legal definition of a “medicinal product” under EU law. Article 1(2) of Directive 2001/83/EC defines a medicinal product as any substance or combination of substances:

1. Presented as having properties for treating or preventing disease in human beings; or
2. That may be used in or administered to human beings with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.

The second limb of this definition — the “functional” definition — is particularly significant. A peptide need not be explicitly marketed as a medicine for it to fall within this definition. If it exerts a pharmacological action, it may qualify. GLP-1 analogues, which act on the GLP-1 receptor to modulate insulin secretion and appetite signalling, are a textbook example of compounds that meet this functional definition.

Key regulatory references (July 2026)

Instrument	Relevance	Source
Directive 2001/83/EC	Defines “medicinal product”; sets authorisation requirements	EUR-Lex
Regulation (EC) 726/2004	Centralised EMA authorisation procedure	EMA / EUR-Lex
HPRA public alerts	Unlicensed GLP-1 products in Ireland	hpra.ie
EMA product pages	Authorisation status of semaglutide, tirzepatide	ema.europa.eu

Unauthorised medicinal products: what the HPRA says

The HPRA has issued multiple public safety communications regarding unlicensed versions of GLP-1 compounds circulating in Ireland. The consistent message is clear: products sold without a valid marketing authorisation may be counterfeit, substandard, or fraudulently labelled, and there is no independent assurance of their identity, purity, or safety.

Key points from HPRA public communications (as of July 2026):

• Unlicensed injectable products claiming to contain semaglutide or similar molecules have been identified in Ireland and across the EU.
• These products may contain incorrect or inconsistent quantities of the active substance, harmful impurities, or entirely different compounds.
• The HPRA urges the public to obtain medicines only through licensed pharmacies and on the advice of a registered healthcare professional.

The HPRA’s alerts page at hpra.ie is the most reliable place to check for current warnings. This editorial team does not reproduce HPRA alerts verbatim because they are updated regularly and our reproduction would inevitably lag the source.

Research context: what “research-only” means and does not mean

Some synthetic peptides are marketed with the description “for research use only” or “not for human consumption”. It is worth being precise about what this label does and does not signify in a regulatory context.

In the EU and Irish legal framework, the “research use” designation does not exempt a product from medicines legislation if it is presented or used in a way that falls within the medicinal product definition. Labelling something “research only” is not a blanket carve-out from HPRA oversight. The substance, its intended use, and how it is marketed are all part of the regulatory picture.

Legitimate research contexts — for example, academic or pharmaceutical research conducted under appropriate ethical and regulatory approvals — operate under separate frameworks including clinical trial authorisation. These are highly regulated environments, distinct from the retail sale of research peptides to individual consumers.

What verification means in this regulatory context

Understanding the HPRA framework clarifies why quality verification — reading a COA, checking identity by LC-MS, confirming purity by HPLC — matters so much, and also why it has limits. Verification tells you something about the analytical quality of a specific batch: whether the molecule declared is actually present, and at what purity. It does not:

• Confer any regulatory authorisation on the product
• Replace the assessment of a licensed doctor
• Confirm sterility, endotoxin levels, or fitness for human use
• Guarantee the absence of unknown impurities not covered by the testing method used

Verification is a necessary step in understanding what a product is. It is not a sufficient condition for concluding what to do with it. That distinction is at the heart of what The Record tries to explain.

Where to find authoritative information

For current, authoritative information about the regulatory status of specific compounds in Ireland and the EU, these are the primary sources:

• HPRA — hpra.ie: product authorisation database, public safety alerts, guidance documents.
• EMA medicines database: marketing authorisation status for centrally authorised products.
• EUR-Lex: full text of EU legislation including Directive 2001/83/EC.

Any account that does not cite these primary sources should be treated with caution. This includes this article: use it as an orientation, then go to the primary sources for accuracy.